ERBB2 and breast carcinoma: However, targeting HER2 via monoclonal antibodies, e.g., trastuzumab, has been a main therapeutic tool in HER2-overexpressing breast cancer, as proven by the NSABP B-47 trial, in which no survival benefit was observed in HER2-low expressing patients [69].